EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient

Takumi Nishikawa iD, Masuho Saburi iD, Shogo Urabe iD, Eiichi Ohtsuka iD

Cancer Reports · 2025

DOI: 10.1002/cnr2.70349 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Reports, 2025. Verfasst von Takumi Nishikawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oita Prefectural Hospital, Oita, Japan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antibodies, Bispecific, Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Agents, Immunological. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Richter syndrome (RS) is an aggressive transformation of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with poor prognosis. No standard treatment for RS has been established. Epcoritamab, a CD3xCD20 bispecific antibody, may offer clinical benefit. Case An 80‐year‐old woman was diagnosed with SLL in 2017 and remained untreated for nearly 6 years. In 2023, she developed a bulky abdominal tumor. Although the initial biopsy showed SLL progression without transformation, subsequent treatments with acalabrutinib, venetoclax plus rituximab, and bendamustine plus rituximab failed. In 2024, transformation to diffuse large B‐cell lymphoma‐type RS (DLBCL‐RS) was confirmed. Two lines of cytotoxic regimens were ineffective, with rapid tumor growth. Epcoritamab was initiated as third‐line therapy. Grade 1–3 cytokine release syndrome occurred but resolved with standard management. No neurotoxicity was observed. Partial response (PR) was achieved by week 12, and the patient has maintained PR for 10 months. Infections including COVID‐19 and cytomegalovirus were managed successfully, and immunoglobulin replacement was introduced for hypogammaglobulinemia.

Conclusion

This case highlights the potential of epcoritamab as an important treatment option for elderly patients with refractory DLBCL‐RS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntibodies, BispecificLeukemia, Lymphocytic, Chronic, B-CellAntineoplastic Agents, ImmunologicalHumansFemaleAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCOVID-19SARS-CoV-2

Stichwörter der Autor:innen

Richter syndromechronic lymphocytic leukemiadiffuse large B‐cell lymphomaepcoritamabsmall lymphocytic lymphoma

Substanzen

Antibodies, BispecificAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
  • Department of Pathology, Oita Prefectural Hospital, Oita, Japan.

ORCID-Profile: Takumi Nishikawa, Masuho Saburi, Shogo Urabe, Eiichi Ohtsuka

Zitieren

APA

Nishikawa, T., Saburi, M., Urabe, S., & Ohtsuka, E. (2025). Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient. Cancer Reports. https://doi.org/10.1002/cnr2.70349

Vancouver

Nishikawa T, Saburi M, Urabe S, Ohtsuka E. Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient. Cancer Reports. 2025. doi:10.1002/cnr2.70349

BibTeX
@article{Nishikawa2025,
  author = {Nishikawa, Takumi and Saburi, Masuho and Urabe, Shogo and Ohtsuka, Eiichi},
  title = {Disease Control and Manageable Toxicity With Epcoritamab in Refractory Diffuse Large B‐Cell Lymphoma‐Type Richter Syndrome: A Case Report in an Elderly Patient},
  journal = {Cancer Reports},
  year = {2025},
  doi = {10.1002/cnr2.70349}
}
Kostenlos starten →